Our website use cookies to improve and personalize your experience and to display advertisements (if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies.

U.S. FDA approves Biogen Alzheimer’s drug, hailed as ‘a big day’

U.S. FDA approves Biogen Alzheimer’s drug, hailed as ‘a big day’

DEENA BEASLEY and JULIE STEENHUYSEN U.S. regulators on Monday approved Biogen Inc's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease despite controversy over whether the clinical evidence proves the drug works. Aducanumab aims to remove sticky deposits of a protein called amyloid-beta from the brains of patients in earlier stages of Alzheimer's in order to stave off its ravages, which include memory loss and the inability to care for one's self. "This is good news for patients with Alzheimer's disease. We've not had a disease-modifying therapy approved ever," said Dr Ronald Petersen, an Alzheimer's disease…
Read More